IL179241A - Using a local aya compound linked to the ywtd region on the lrp5 or lrp6 receptor to prepare for stimulating or enhancing bone formation or bone transduction - Google Patents

Using a local aya compound linked to the ywtd region on the lrp5 or lrp6 receptor to prepare for stimulating or enhancing bone formation or bone transduction

Info

Publication number
IL179241A
IL179241A IL179241A IL17924106A IL179241A IL 179241 A IL179241 A IL 179241A IL 179241 A IL179241 A IL 179241A IL 17924106 A IL17924106 A IL 17924106A IL 179241 A IL179241 A IL 179241A
Authority
IL
Israel
Prior art keywords
lrp5
stimulation
binds
enhancement
preparation
Prior art date
Application number
IL179241A
Other languages
English (en)
Hebrew (he)
Other versions
IL179241A0 (en
Original Assignee
Enzo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzo Therapeutics Inc filed Critical Enzo Therapeutics Inc
Publication of IL179241A0 publication Critical patent/IL179241A0/en
Publication of IL179241A publication Critical patent/IL179241A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL179241A 2004-05-19 2006-11-13 Using a local aya compound linked to the ywtd region on the lrp5 or lrp6 receptor to prepare for stimulating or enhancing bone formation or bone transduction IL179241A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/849,067 US8637506B2 (en) 2003-09-22 2004-05-19 Compositions and methods for bone formation and remodeling
PCT/US2005/017199 WO2005115354A2 (en) 2004-05-19 2005-05-18 Compositions and methods for bone formation and remodeling

Publications (2)

Publication Number Publication Date
IL179241A0 IL179241A0 (en) 2007-03-08
IL179241A true IL179241A (en) 2016-04-21

Family

ID=35451375

Family Applications (1)

Application Number Title Priority Date Filing Date
IL179241A IL179241A (en) 2004-05-19 2006-11-13 Using a local aya compound linked to the ywtd region on the lrp5 or lrp6 receptor to prepare for stimulating or enhancing bone formation or bone transduction

Country Status (7)

Country Link
US (1) US8637506B2 (https=)
EP (3) EP3150255A1 (https=)
JP (1) JP2008505190A (https=)
CN (1) CN101316627A (https=)
CA (6) CA2771941C (https=)
IL (1) IL179241A (https=)
WO (1) WO2005115354A2 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6780609B1 (en) * 1998-10-23 2004-08-24 Genome Therapeutics Corporation High bone mass gene of 1.1q13.3
US6770461B1 (en) * 1998-10-23 2004-08-03 Genome Therapeutics Corporation High bone mass gene of 11q13.3
US20040221326A1 (en) * 2001-05-11 2004-11-04 Philip Babij Transgenic animal model of bone mass modulation
JP2004537289A (ja) * 2001-05-11 2004-12-16 ゲノム　セラピューティックス　コーポレーション 骨量および脂質レベルを調整するｈｂｍ変異型
US20030219793A1 (en) * 2002-10-04 2003-11-27 Carulli John P. High bone mass gene of 11q13.3
US7485460B2 (en) * 2003-05-21 2009-02-03 Tulane University Health Sciences Center Enhanced growth of adult stem cells with Dkk-1
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
US8367822B2 (en) 2003-09-22 2013-02-05 Enzo Therapeutics, Inc. Compositions and methods for bone formation and remodeling
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US20120178697A9 (en) * 2003-09-22 2012-07-12 Jie Zheng Compositions and methods for the inhibition of dishevelled proteins
US8637506B2 (en) * 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
US20100041599A1 (en) 2006-11-14 2010-02-18 Dakai Liu Compositions and methods for bone formation, bone remodeling and toxin protection
US9052324B2 (en) * 2004-05-19 2015-06-09 Enzo Biochem, Inc. Compounds and assays for controlling Wnt activity
US8343922B2 (en) * 2004-05-19 2013-01-01 Enzo Biochem, Inc. Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
CA2685737A1 (en) * 2007-04-30 2008-11-06 Washington University Methods and compositions for the treatment of cancer
WO2008144659A2 (en) * 2007-05-18 2008-11-27 Board Of Regents, The University Of Texas System Dickkopf-1 (dkk1) as a universal tumor vaccine for immunotherapy of cancers
KR20100091170A (ko) * 2007-11-02 2010-08-18 노파르티스 아게 저밀도-지단백질 수용체-관련 단백질 ６ (ｌｒｐ６)을 조정하기 위한 분자 및 방법
CA2705923A1 (en) * 2007-11-16 2009-05-22 Nuvelo, Inc. Antibodies to lrp6
US8716243B2 (en) 2008-05-28 2014-05-06 St. Jude Childen's Research Hospital Methods of effecting Wnt signaling through Dkk structural analysis
WO2010108001A2 (en) * 2009-03-18 2010-09-23 The Brigham And Women's Hospital, Inc. Agents and methods for tissue repair and regeneration
PE20120475A1 (es) 2009-05-12 2012-05-05 Pfizer Anticuerpos especificos para dkk-1
EP4234698A3 (en) 2010-05-06 2023-11-08 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
KR20130066631A (ko) 2010-05-06 2013-06-20 노파르티스 아게 치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 다가 항체에 대한 조성물 및 사용 방법
US9493541B2 (en) 2010-06-07 2016-11-15 Joshua Rabbani Antibodies specific for sulfated sclerostin
US9617323B2 (en) 2010-06-07 2017-04-11 Joshua Rabbani Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor
US9403882B2 (en) 2010-06-07 2016-08-02 Joshua Rabbani Sulfation of Wnt pathway proteins
US11167011B2 (en) 2010-06-07 2021-11-09 Enzo Biochem, Inc. Methods for treating bone loss using sclerostin peptides
AU2012205583B2 (en) * 2011-01-11 2016-01-21 Fate Therapeutics, Inc. Novel Wnt compositions and therapeutic uses of such compositions
KR101303941B1 (ko) 2011-03-31 2013-09-05 연세대학교 산학협력단 피마자 추출물을 유효성분으로 함유하는 골 질환 예방 및 치료용 조성물
CN104039830A (zh) 2011-11-04 2014-09-10 诺华股份有限公司 低密度脂蛋白相关蛋白6(lrp6)-半寿期延长物构建体
CN103966229A (zh) * 2014-05-09 2014-08-06 中山大学 bbeAMP基因、其编码的蛋白质、以bbeAMP为目的基因生产的融合蛋白及其应用
US11142577B2 (en) 2014-09-12 2021-10-12 The Board Of Trustees Of The Leland Stanford Junior University WNT signaling agonist molecules
CN106367517A (zh) * 2016-09-28 2017-02-01 湖北工业大学 一种低密度脂蛋白受体相关蛋白5基因突变检测的试剂及应用
EP3732201A4 (en) 2017-12-19 2022-04-20 Surrozen Operating, Inc. WNT SURROGATES AND THEIR USES
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
CN111655729B (zh) 2017-12-19 2023-10-20 瑟罗泽恩奥普瑞汀公司 抗卷曲蛋白抗体和使用方法
CN111632147A (zh) * 2020-06-07 2020-09-08 重庆医科大学 骨细胞Wnt激活剂在制备骨折加速愈合、防治骨不连及不运动或失重骨丢失药物中的应用
WO2023039460A1 (en) * 2021-09-08 2023-03-16 Baylor College Of Medicine Methods and compositions for immune control through dickkopf-1
CN115309402B (zh) * 2022-07-13 2023-10-24 国网江苏省电力有限公司信息通信分公司 一种可量化差异的异构执行程序集合构成方法及装置

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS562623A (en) * 1979-06-21 1981-01-12 Matsushita Electric Industrial Co Ltd Electrode
DE69420649T2 (de) * 1993-08-19 2000-05-04 Advanced Micro Devices, Inc. Voll differentieller Operationsverstärker mit niedriger Versorgungsspannung
US7244577B2 (en) 1997-04-15 2007-07-17 Merck & Co., Inc. Method of screening for modulator of LRP5 activity
DE19747418C1 (de) * 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
AU3510200A (en) * 1999-03-05 2000-09-21 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
EP1280901B1 (de) 2000-03-29 2005-01-26 Max-Planck-Gesellschaft Raumform von tpr-strukturmotiv enthaltenden polypeptiden mit chaperon-bindungsfunktion, deren kristalle und verbindungen zur inhibierung derartiger polypeptide
US7713526B2 (en) * 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
IL158750A0 (en) 2001-05-17 2004-05-12 Genome Therapeutics Corp Reagents and methods for modulating dkk-mediated interactions
US20040038860A1 (en) * 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
JP2005511593A (ja) 2001-11-08 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド 骨粗鬆症を治療するための組成物及び方法
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
US20050084494A1 (en) 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
US9046537B2 (en) * 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
US20120178697A9 (en) 2003-09-22 2012-07-12 Jie Zheng Compositions and methods for the inhibition of dishevelled proteins
US8637506B2 (en) 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8367822B2 (en) * 2003-09-22 2013-02-05 Enzo Therapeutics, Inc. Compositions and methods for bone formation and remodeling
US8343922B2 (en) 2004-05-19 2013-01-01 Enzo Biochem, Inc. Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
MX2007001221A (es) 2004-08-04 2007-03-23 Amgen Inc Anticuerpos para proteina dickkopf-1 (dkk-1).
US7838252B2 (en) 2005-02-17 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating a subject having an anthrax toxin mediated condition

Also Published As

Publication number Publication date
EP3150255A1 (en) 2017-04-05
CA2771941A1 (en) 2005-12-08
EP1758562A2 (en) 2007-03-07
CA2771941C (en) 2015-03-31
EP2409732B1 (en) 2016-04-06
CA2772033C (en) 2016-05-17
US20060198791A2 (en) 2006-09-07
WO2005115354A2 (en) 2005-12-08
CA2771951A1 (en) 2005-12-08
CA2771940A1 (en) 2005-12-08
CA2772033A1 (en) 2005-12-08
CA2567023C (en) 2012-07-03
CA2771940C (en) 2016-01-12
JP2008505190A (ja) 2008-02-21
CA2772029A1 (en) 2005-12-08
WO2005115354A3 (en) 2007-09-13
CA2772029C (en) 2016-05-17
CN101316627A (zh) 2008-12-03
CA2567023A1 (en) 2005-12-08
EP2409732A1 (en) 2012-01-25
EP1758562B1 (en) 2012-12-05
US8637506B2 (en) 2014-01-28
CA2771951C (en) 2014-07-08
IL179241A0 (en) 2007-03-08
US20050196349A1 (en) 2005-09-08
EP1758562A4 (en) 2009-07-22

Similar Documents

Publication Publication Date Title
IL179241A (en) Using a local aya compound linked to the ywtd region on the lrp5 or lrp6 receptor to prepare for stimulating or enhancing bone formation or bone transduction
TWI370135B (en) Analogs of ghrelin substituted at the n-terminal
CL2008000316A1 (es) Compuestos derivados de 2-metilsulfonil-1,2,3,4-tetrahidroisoquinolina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la diabetes, hiperlipidemia, enfermedades cardiacas, artritis, osteoporosis, hipertension, catara
BRPI0919876A8 (pt) Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo.
BRPI0816597A2 (pt) "composto, composição farmacêutica, combinação, uso de um composto, método para tratar um indivíduo aflifido com uma consição patológica ou doença e método de modulação de uma atividade um receptor b2 adrenérgico"
ES2411907T8 (es) Uso terapéutico de anticuerpos antirreceptor TWEAK
HRP20250807T8 (hr) Protutijela koja vežu ljudski cgrp receptor
EP2211724A4 (en) Pivot studs SEAM ANCHOR KIT
IL204407A0 (en) 3' substituted compounds having 5 - ht6 receptor affinity
BRPI0816326A2 (pt) Compostos que modulam cálcio intracelular
DE602005015577D1 (de) Harnstoff-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
BRPI0819703A2 (pt) Uso de inibidores de proteína tirosina fosfatase e hormônio de crescimento humano, uso de igf1 e um inibidor de proteína tirosina fosfatase e composição de combinação farmacêutica para o tratamento de atrofia muscular e distúrbios relacionados
WO2009137843A9 (en) Nmda receptor antagonists for the treatment of neuropsychiatric disorders
ZA200806067B (en) Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
CL2004000449A1 (es) Compuestos derivados de imidazol-4-il-etinil-piridina, para tratar trastornos mediados por el receptor mglur5; procedimiento de preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en
CR10245A (es) "nuevas combinaciones terapéuticas para el tratamiento de la depresión"
IL195514A0 (en) Substituted pyridiyl amide compounds as modulators of the histamine h3 receptor
ATE445692T1 (de) Polydextrose induzierte zweiphasige zusammensetzung
FR2930030B1 (fr) Dispositif de controle de la qualite d'une surface
IL201974A0 (en) 4' substituted compounds having 5-ht6 receptor affinity
EP2227242A4 (en) BONE MORPHOGUE PROTEIN BINDING SPEPTIDE
ATE463481T1 (de) Cyclopropylamine als modulatoren des histamin-h3- rezeptors
IL290852A (en) Treatment of liver disease or disorder involving actrii receptor antagonists
IL225745A0 (en) Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds are suitable for the treatment of disorders that respond to dopamine 3d receptor regulation
BRPI0818719A2 (pt) Composição para o tratamento de doença articular

Legal Events

Date Code Title Description
FF Patent granted
KB20 Patent renewed for 20 years